The deal – which is expected to be sealed at the end of the month – comes after a 20-year business partnership between the pair, with Engefiltro serving as an exclusive distributor in various market segments.
But by actually taking ownership of Engefiltro, headquartered in Sao Paulo, Pall hopes to strengthen its grip on the fast-growing Latin American market.
Felix Diaz, president at Pall Latin America, told in-PharmaTechnologist: “Engefiltro's capabilities are complementary to Pall's capabilities, so operating as one organisation we can provide even more focused activities in support of customers needs.
“The acquisition extends Pall Corporation's capabilities, better positioning our technologies and products in all market segments that we serve. “
When we questioned if a hidden agenda behind the sudden shift in a successful two-decade-long relationship was born of a desire to gain better access to any particular projects in the fast-paced Latin America market, Diaz replied: “There was no particular project that triggered this acquisition.”
The terms of the deal were not disclosed.
Pharmaceuticals and beyond
Engefiltro’s customer baserepresents a broad spectrum of the national economy including the mining, oil and gas, chemical and petrochemical, power generation, food processing, and pharmaceutical industries; all industries which lie within Pall's scope.
Diaz told us: “Engefiltro will continue to serve all the markets that they are currently serving, and we will continue to serve all the markets that Engefiltro is currently serving.”
Eric Krasnoff, Pall CEO and president, said: “Brazil is already the world’s seventh largest economy and among the fastest growing. Its current size, market diversity and growth plans demand a local Pall presence.
“We are delighted to welcome Engefiltro's employees to the Pall family and will do everything we can to further enhance theirability to serve customers and grow the business.”